Your browser has either disabled or does not support javascript. Javascript is required for full website experience.
Aridis Pharmaceuticals Inc.
ARDS
$
6.48
1.6%
Tue October 27th, 2020
09:30
Press Releases
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
PR Newswire
Wed October 14th, 2020
09:30
Press Releases
Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering
PR Newswire
Fri September 11th, 2020
11:27
Analysis
Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha
Tue September 8th, 2020
09:30
Press Releases
Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501
PR Newswire
Fri September 4th, 2020
17:32
Press Releases
Aridis Pharmaceuticals to Present at Upcoming Investor Conferences
PR Newswire
Fri June 26th, 2020
09:30
Press Releases
Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
PR Newswire
Mon June 22nd, 2020
09:30
Press Releases
Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial
PR Newswire
Mon June 15th, 2020
09:30
Press Releases
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
PR Newswire
